Nutraceutical Combination in Patients With Low-grade Systemic Inflammation

Inclusion Criteria: * LDL cholesterol \<160 mg/dl (4,14 mmol/l); * hsCRP \>2 mg/L; Exclusion Criteria: * triglycerides \>500 mg/dL (5.6 mmol/L); * current or previous treatment with lipid-lowering drugs or with other drugs supposed to modify vascular damage and/or repair (antiplatelet, anti-hypertensive and antioxidant drugs); * current or previous treatment with hormone replacement therapy for menopause vasomotor symptoms; * evidence of liver dysfunction or alanine-aminotransferase (ALT) levels twice above the upper normal limit; * creatin-kinase (CK) levels thrice above the upper normal limit * history or clinical evidence of previous or current cardiovascular disease; * presence of strong cardiovascular risk factors such as: serum creatinine levels \>2 mg/dL, diabetes mellitus, uncontrolled systemic arterial hypertension (systolic blood pressure \>190 mg/dL or diastolic blood pressure \>100 mg/dL); history of cancer in the former 5 years before recruitment; not adequately treated hypothyroidism (TSH levels \>1,5 times the upper normal limit); * history of malignancy in the previous 5 years before screening; * not adequately treated hypothyroidism (TSH levels \>1,5 times the upper normal limit); * previous or current alcohol or drugs abuse; * history or clinical evidence of chronic inflammatory disease such as severe arthritis, systemic lupus erythematosus or chronic inflammatory bowel disease; * current or previous use of immunosuppressant agents or long term glucocorticoids * history or clinical evidence of any severe concomitant disease which may compromise subject's safety or its possibility to carry out the study.